Those investigators reported that the MASLD prevalence will increase between 6% and 20%, MASH prevalence will increase 2035%, and new cases of HCC, decompensated cirrhosis, and CLD-related mortality could increase by anywhere from 65% to 100% [41]
If anyone finds the direct comment page, please share it, as I would like to submit and elaborate on my comment below: As a patient, I hope the FDA considers access in the definition of clinical need. For many patients, GLP-1 therapy is not cosmetic
This is basically asking your insurance company for permission to cover the medication, especially if it's not automatically on their list of approved drugs
Comprehensive Benefits: Alleviates swelling, improves flexibility, and supports cardiovascular health and overall joint function recovery
Youre just not, your cells arent hearing it
Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding Novo Nordisk's shares plunged more than 20% Tuesday, after the company cut the forecast for its flagship obesity drug